x

Política de cookies

Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso.

Más información
Permissions Requests - Help - - Sign up - Phone number 902 888 740
Search

2017 FI

1.644
© Thomson Reuters, Journal Citation Reports, 2017

Indexed in:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME Cancerlit, Bibliomed, CabHealth, Scisearch, HealthStar, Scopus, Prous, Science Intergews, Science Citation Index Expanded.

Metrics

  • Impact Factor: 1.644 (2017)
  • CiteScore 2017: 1.24
    Read more
  • SCImago Journal Rank (SJR):0,504
  • Source Normalized Impact per Paper (SNIP):0,791

© Clarivate Analytics, Journal Citation Reports 2017

Allergol Immunopathol (Madr) 2018;46:226-34 - DOI: 10.1016/j.aller.2017.07.003
Original Article
Comparing the effects of fluticasone, anti-IgE and anti-TNF treatments in a chronic asthma model
M.Y. Ozkarsa,, , O. Keskina, M. Tokurb, M. Ulaslic, B. Gogebakand, H. Ciralike, E. Kucukosmanoglua, C. Demirelf, S. Oztuzcuc, H. Kahramang
a Department of Pediatric Allergy and Immunology, Gaziantep University School of Medicine, Gaziantep, Turkey
b Department of Thoracic Surgery, Kahramanmaras Sutcu Imam University School of Medicine, Kahramanmaras, Turkey
c Department of Medical Biology, Gaziantep University School of Medicine, Gaziantep, Turkey
d Department of Medical Biology, Mustafa Kemal University School of Medicine, Hatay, Turkey
e Department of Pathology, Kahramanmaras Sutcu Imam University School of Medicine, Kahramanmaras, Turkey
f Department of Biophysics, Gaziantep University School of Medicine, Gaziantep, Turkey
g Department of Pulmonology, Kahramanmaras Sutcu Imam University School of Medicine, Kahramanmaras, Turkey
Received 18 April 2017, Accepted 29 July 2017
Abstract
Background

Corticosteroids are used in the treatment of asthma. The aim of this study was to determine the efficacy of anti-IgE and anti-TNF alpha as asthma treatments.

Methods

A mouse model of chronic asthma was developed. The fluticasone group was exposed to fluticasone and the anti-IgE and anti-TNF groups were administered anti-IgE or anti-TNF. IL-4, and IgE levels were measured, and histological analysis, pathological analysis and miRNA-126, miRNA-133a analyses were applied.

Results

The cell concentration in the BAL fluid decreased in all the treatment groups. The rate of perivascular and peribronchial cell infiltration decreased in the lung in the high-dose anti-IgE and anti-TNF groups. Smooth muscle thickness decreased in the lung tissue in the low-dose anti-IgE and anti-TNF groups. Bronchial wall thickness decreased in the lung tissue in the fluticasone+anti-IgE group. The IL-4 level in BAL fluid decreased in the high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups. IgE levels increased in the BAL fluid in the high-dose anti-IgE and anti-TNF groups. The lymphocyte level increased in the BAL fluid in the high-dose anti-IgE group. The macrophage level decreased in the BAL fluid in the anti-TNF group. The relative expression of miRNA-126 increased in all groups. The relative expression of miRNA-133a decreased in the placebo and fluticasone groups. The relative expression of miRNA-133a increased in the low-dose anti-IgE, high-dose anti-IgE, fluticasone+anti-IgE and anti-TNF groups.

Conclusions

The results showed that anti-IgE is successful as a treatment. Fluticasone+anti-IgE and anti-TNF were seen to be superior to other therapeutic modalities when used for prophylaxis.

Keywords
Anti-IgE, Anti-TNF, Asthma, Fluticasone, IgE, IL-4, Lung histopathology, miRNA-126, miRNA-133a
Download PDF

Article

Read the complete contents of this article

Already registered?